CANNASSURE THERAPEUTICS LTD Financials Cannassure Therapeutics Ltd
Equities
CSURE-M
IL0001110134
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,511 ILa | +0.73% |
|
+8.71% | +212.84% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 60.21 | 75.53 | 33.54 | 4.605 | 4 |
| Enterprise Value (EV) 1 | 56.48 | 83.86 | 43.93 | 34.57 | 6.434 |
| P/E ratio | -3.52 x | -2.44 x | -2.03 x | -0.84 x | -2.24 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 21,598,659 x | 985,816 x | 136,314 x | 363,725 x |
| EV / Revenue | - | 23,980,129 x | 1,291,150 x | 1,023,292 x | 585,038 x |
| EV / EBITDA | -3.56 x | -3.47 x | -3.69 x | -260 x | 2.5 x |
| EV / FCF | -2,970,103 x | -5,623,842 x | -7,700,674 x | -2,701,456 x | 518,420 x |
| FCF Yield | -0% | -0% | -0% | -0% | 0% |
| Price to Book | 2.94 x | 6.86 x | 6.61 x | -3.42 x | -1.32 x |
| Nbr of stocks (in thousands) | 541 | 721 | 828 | 828 | 828 |
| Reference price 2 | 111.3 | 104.8 | 40.50 | 5.560 | 4.830 |
| Announcement Date | 05/04/20 | 31/03/21 | 31/03/22 | 26/03/23 | 27/03/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 3.497 | 34.02 | 33.78 | 11 |
| EBITDA 1 | -14.72 | -15.86 | -24.14 | -11.9 | -0.133 | 2.577 |
| EBIT 1 | -14.73 | -16.6 | -27.99 | -15.77 | -2.587 | 1.57 |
| Operating Margin | - | - | -800.49% | -46.35% | -7.66% | 14.28% |
| Earnings before Tax (EBT) 1 | -24.36 | -17 | -28.54 | -16.52 | -5.474 | -1.786 |
| Net income 1 | -24.36 | -17 | -28.54 | -16.52 | -5.474 | -1.786 |
| Net margin | - | - | -816.04% | -48.55% | -16.2% | -16.24% |
| EPS 2 | -96.35 | -31.58 | -43.00 | -20.00 | -6.609 | -2.160 |
| Free Cash Flow | - | -19.02 | -14.91 | -5.705 | -12.8 | 12.41 |
| FCF margin | - | - | -426.4% | -16.77% | -37.88% | 112.85% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 481.62% |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 20/02/19 | 05/04/20 | 31/03/21 | 31/03/22 | 26/03/23 | 27/03/24 |
1ILS in Million2ILS
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 8.33 | 10.4 | 30 | 2.43 |
| Net Cash position 1 | 21.1 | 3.73 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.3451 x | -0.8734 x | -225.3 x | 0.9445 x |
| Free Cash Flow | - | -19 | -14.9 | -5.7 | -12.8 | 12.4 |
| ROE (net income / shareholders' equity) | -220% | -73.6% | -166% | -205% | -293% | 81.7% |
| ROA (Net income/ Total Assets) | -69% | -34.5% | -56.9% | -31.1% | -4.23% | 4.75% |
| Assets 1 | 35.33 | 49.35 | 50.14 | 53.16 | 129.3 | -37.56 |
| Book Value Per Share 2 | 44.60 | 37.80 | 15.30 | 6.130 | -1.620 | -3.660 |
| Cash Flow per Share 2 | 35.90 | 16.20 | 0.9000 | 3.560 | 0.2100 | 0.0100 |
| Capex 1 | 4.78 | 12.5 | 4.2 | 1.5 | 0.11 | - |
| Capex / Sales | - | - | 119.99% | 4.4% | 0.33% | - |
| Announcement Date | 20/02/19 | 05/04/20 | 31/03/21 | 31/03/22 | 26/03/23 | 27/03/24 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +212.84% | 9.07M | |
| -.--% | 339M | |
| +35.39% | 264M | |
| +28.87% | 266M | |
| +42.44% | 185M | |
| +167.98% | 152M | |
| -14.29% | 145M | |
| +51.09% | 137M | |
| -7.69% | 79.94M | |
| +50.00% | 45.2M |
- Stock Market
- Equities
- CSURE-M Stock
- Financials Cannassure Therapeutics Ltd
